ライフサイエンスコーパス: necitumumab

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 tumumab for 6 cycles followed by maintenance necitumumab.

2 e for a maximum of six cycles alone, or with necitumumab 800 mg on days 1 and 8.

3 Necitumumab 800 mg, administered intravenously over a mi

4 and cisplastin chemotherapy with or without necitumumab according to a block randomisation scheme (b

5 -effectiveness ratios (ICERs) for the use of necitumumab across a range of values for its cost.

6 pared standard chemotherapy with and without necitumumab as first-line treatment of mSqCLC, to evalua

7 c sensitivity analyses established that when necitumumab cost less than $563 and less than $1309 per

8 for 6 cycles or gemcitabine, cisplatin, and necitumumab for 6 cycles followed by maintenance necitum

9 provide a value-based range for the cost of necitumumab from $563 to $1309 per cycle.

10 e reported in 15 (5%) of 304 patients in the necitumumab group versus nine (3%) of 312 patients in th

11 Necitumumab is a second-generation recombinant human imm

12 Necitumumab is a second-generation, recombinant, human i

13 fy potentially useful predictive biomarkers, necitumumab is unlikely to provide benefit in this patie

14 tients and randomly assigned them to receive necitumumab plus gemcitabine and cisplatin (n=545) or ge

15 reported for 66 (12%) of 538 patients in the necitumumab plus gemcitabine and cisplatin group and 57

16 More patients in the necitumumab plus gemcitabine and cisplatin group had gra

17 all survival was significantly longer in the necitumumab plus gemcitabine and cisplatin group than in

18 omagnesaemia (47 [9%] of 538 patients in the necitumumab plus gemcitabine and cisplatin group vs six

19 In the necitumumab plus gemcitabine and cisplatin group, the nu

20 is study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcit

21 Overall, we found that the safety profile of necitumumab plus gemcitabine and cisplatin was acceptabl

22 omly assigned 633 patients to receive either necitumumab plus pemetrexed and cisplatin (n=315) or pem

23 Patients in the necitumumab plus pemetrexed and cisplatin group had more

24 events, including deaths, was higher in the necitumumab plus pemetrexed and cisplatin group than in

25 se events were likewise more frequent in the necitumumab plus pemetrexed and cisplatin group than in

26 ival of 11.3 months (95% CI 9.5-13.4) in the necitumumab plus pemetrexed and cisplatin group versus 1

27 We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexe

28 The SQUIRE trial demonstrated that adding necitumumab to chemotherapy for patients with metastatic

29 Our findings show that the addition of necitumumab to gemcitabine and cisplatin chemotherapy im

30 no evidence to suggest that the addition of necitumumab to pemetrexed and cisplatin increases surviv

31 In the base case analysis, the addition of necitumumab to the treatment regimen produced an increme

32 Necitumumab was continued after the end of chemotherapy

33 was 90% confidence that the ICER for adding necitumumab would be less than $100 000 per QALY and les

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。